Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · IEX Real-Time Price · USD
149.45
-4.94 (-3.20%)
At close: Mar 28, 2024, 4:00 PM
150.00
+0.55 (0.37%)
After-hours: Mar 28, 2024, 7:42 PM EDT

Alnylam Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2003
Net Income
-440.24-1,131.16-852.82-858.28-886.12-761.5-490.87-410.11-290.07-360.4
Upgrade
Depreciation & Amortization
97.0385.5589.6974.4454.3715.2511.915.1319.0511.93
Upgrade
Share-Based Compensation
221.68230.65165.72139.87174.84157.7592.8277.0446.7733.75
Upgrade
Other Operating Activities
225.69273.68-44.2829.01378.4825.883.3710.2435.12149.08
Upgrade
Operating Cash Flow
104.16-541.27-641.69-614.96-278.43-562.62-382.79-307.7-189.14-165.64
Upgrade
Capital Expenditures
-62.21-72.06-76.37-70.36-140.16-126.89-104.21-64.56-12.95-8.96
Upgrade
Acquisitions
000000000-25
Upgrade
Change in Investments
-269.7246.11-192.73-359.86-270.52399.83-186.15207.15-308.37-514.85
Upgrade
Other Investing Activities
-4.44-4.69-4.2-5.3-7-----
Upgrade
Investing Cash Flow
-336.35169.35-273.3-435.52-417.68272.95-290.36142.59-321.32-548.81
Upgrade
Share Issuance / Repurchase
147.46259.36246.27299.98853.1865.471,24527.83616.18736.47
Upgrade
Debt Issued / Paid
0135.3950020000-12015000
Upgrade
Other Financing Activities
24.6731500.85495-30-----
Upgrade
Financing Cash Flow
172.13425.751,247994.98823.1865.471,125177.83616.18736.47
Upgrade
Exchange Rate Effect
6.39-7.43-9.024.92-0.0800000
Upgrade
Net Cash Flow
-53.6746.4323.11-50.58127-224.2451.7412.72105.7222.01
Upgrade
Free Cash Flow
41.95-613.33-718.07-685.32-418.58-689.5-487-372.26-202.09-174.6
Upgrade
Free Cash Flow Margin
2.29%-59.12%-85.05%-139.05%-190.48%-920.47%-541.64%-789.37%-491.74%-345.33%
Upgrade
Free Cash Flow Per Share
0.34-5.04-6.06-5.96-3.83-6.86-5.38-4.35-2.41-2.35
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).